Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.

 Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.


Sobi has a diversified and growth-oriented commercial product portfolio within three business lines.
To products

Our pipeline

Sobi’s pipeline programs are focused on recombinant protein drugs for specialist indications for the global market.
Read more about Sobi's pipeline

Humanitarian Aid Donation

Haemophilia occurs in every part of the world. The World Federation of Hemophilia (WFH) has highlighted that, globally, only 25% of people affected receive access to treatment. Sobi and Biogen Idec want to be part of changing this.
Read more

Presentation of Sobi's Interim Report April - June 2014

18 July 2014, Sobi's Report for the second quarter 2014 was published - Revenues for the quarter totalled SEK 663 M (520), an increase of 27 per cent.

Share Price


Volume: 463,414
Ticker: SOBI
SSE Large